Article Versions Notes

Santos HS, Poletto E, Vera LNP, Farinon M, Kubaski F, Carneiro PB, Carniel WdS, Giugliani R, Matte U, Teixeira HF, et al. Liposomal CRISPR/Cas9-Mediated Local Genome Editing for Joint Disease in Mucopolysaccharidosis Type I. Pharmaceutics. 2026; 18(3):281. https://doi.org/10.3390/pharmaceutics18030281

Santos, Hallana Souza, Edina Poletto, Luisa Natalia Pimentel Vera, Mirian Farinon, Francyne Kubaski, Paola Barcelos Carneiro, Willian da Silva Carniel, Roberto Giugliani, Ursula Matte, Helder Ferreira Teixeira, and et al. 2026. "Liposomal CRISPR/Cas9-Mediated Local Genome Editing for Joint Disease in Mucopolysaccharidosis Type I" Pharmaceutics 18, no. 3: 281. https://doi.org/10.3390/pharmaceutics18030281

Santos, H. S., Poletto, E., Vera, L. N. P., Farinon, M., Kubaski, F., Carneiro, P. B., Carniel, W. d. S., Giugliani, R., Matte, U., Teixeira, H. F., Schuh, R. S., & Baldo, G. (2026). Liposomal CRISPR/Cas9-Mediated Local Genome Editing for Joint Disease in Mucopolysaccharidosis Type I. Pharmaceutics, 18(3), 281. https://doi.org/10.3390/pharmaceutics18030281